AstraZeneca refused interim injunction on SPC for blockbuster diabetes treatment against Glenmark but swiftly obtains permission to appeal
By EsqSocial Corporation 08/04/25
On March 28, 2025, Michael Tappin KC, sitting as a deputy judge of the High Court, refused to grant AstraZeneca (“AZ”) an interim injunction to restrain Glenmark from launching in the U.K. a generic version of its type 2 diabetes treatment, Forxiga® (dapagliflozin) for an estimated period of one to three months pending a trial decision and final order hearing in ongoing first instance revocation proceedings against AZ’s SPC that protects dapagliflozin. Forxiga® is also used in the treatment of...
By: A&O Shearman